Tag Archives: GNFT

H.C. Wainwright Maintains Their Hold Rating on Genfit SA (GNFT)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Genfit SA (GNFT – Research Report), with a price target of $8.00. The company’s shares closed last Wednesday at $5.12, close to its 52-week low

H.C. Wainwright Sticks to Its Buy Rating for Genfit SA (GNFT)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $46.00. The company’s shares closed last Thursday at $16.75. According to TipRanks.com, Arce is a 4-star analyst

B.Riley FBR Sticks to Its Buy Rating for Genfit SA (GNFT)

In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Genfit SA (GNFT – Research Report), with a price target of $34.00. The company’s shares closed last Monday at $12.95, close to its

Genfit SA (GNFT) Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $43.00. The company’s shares closed last Monday at $16.98. According to TipRanks.com, Mamtani is a 5-star analyst

Genfit SA (GNFT) Receives a Buy from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Genfit SA (GNFT – Research Report) today and set a price target of $43.00. The company’s shares closed last Monday at $16.18. According to TipRanks.com, Mamtani is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Genfit SA (NASDAQ: GNFT), Aquestive Therapeutics Inc (NASDAQ: AQST) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genfit SA (GNFT – Research Report), Aquestive Therapeutics Inc (AQST – Research Report) and Aslan Pharmaceuticals Ltd (ASLN – Research Report) with